Sept. 13, 2022– President Biden’s call for a “moonshot” campaign to cut the death rate from cancer by at least 50% over the next 25 years focuses renewed attention on ensuring access to affordable cancer care for patients living with low incomes and those who live in often-underserved rural communities across the country. The 340B drug pricing program plays a vital role in … [Read more...]
Drugmakers Cutting 340B Discounts Reported Record Revenues Last Year
March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
A 340B Community Comes Together to Celebrate
By Maureen Testoni Feb. 17, 2022– In many ways, last month’s 340B Coalition Winter Conference in San Diego was a cause for celebration. We celebrated the first chance we had to come together in person as a community in two years. And we celebrated the start of a historic year for the 340B drug pricing program, which will turn 30 years old this November. When 340B … [Read more...]
Boehringer Ingelheim Joins in the Attacks on 340B
July 12, 2021– The pharmaceutical giant Boehringer Ingelheim (BI), a manufacturer headquartered in Germany, is the latest company to announce it is cutting off discounts to safety-net hospitals participating in the 340B drug pricing program. If BI goes through with its threat on Aug. 1, it will become the seventh drug company to limit 340B discounts despite strong warnings by … [Read more...]
New Federal 340B Order Is Major Step Toward Restoring Drug Discounts
May 19, 2021– The Health Resources & Services Administration (HRSA) has taken decisive action to put a stop to the actions of six drug companies that are denying 340B drug pricing program discounts for medications dispensed at community pharmacies. The action could lead to the end of a nearly year-long dispute pitting for-profit pharmaceutical companies against nonprofit … [Read more...]
Faces of 340B: A Patient Mission Under Duress
November 8, 2019– Like many safety-net health systems, Centura Health has been using the 340B drug pricing program to keep some of its hospitals operating and to serve all patients regardless of their ability to pay. But continuing Medicare cuts to many of these hospitals are straining that important mission. Centura Health is a 17-hospital system located in Colorado and … [Read more...]
Survey Raises Questions About Duplicate Discounts
Oct. 17, 2019– A newly released survey on the interplay of the 340B drug discount program and Medicaid has raised questions about what federal and state rules are in place to prevent duplicate discounts. The bottom line is that several such rules already exist in all 50 states to prevent pharmaceutical manufacturers from paying both a 340B discount and a Medicaid rebate on the … [Read more...]